PRTA Stock Price, Chart, Stats & News
PRTA chart
Fundamentals
Gross margin | -208.55% |
Operating margin | -2247.50% |
Pretax margin | -2066.16% |
Net margin | -2520.57% |
Effective tax rate | -21.99% |
ROA | -74.69% |
ROE | -73.00% |
D/E | 0.05x |
Interest coverage ratio | – |
PRTA valuation
P/E | – |
P/S | 51.48x |
P/B | 1.78x |
P/CF | -2.98x |
P/FCF | -2.97x |
P/OCF | -2.98x |
PEG | -0.16x |
EV multiple | -4.56x |
About
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease.
Similar securities
Based on sector and market capitalization
